Phase 2 study of dabrafenib plus trametinib in patients with BRAF V600E-mutant metastatic non-small cell lung cancer: Updated 5-year survival rates and genomic analysis.
暂无分享，去创建一个
H. Groen | D. Planchard | J. Mazières | L. Santarpia | F. Barlesi | B. Besse | T. Kim | E. Quoix | C. Baik | R. Kelly | Shirong Zhang | E. Gasal | S. Hashemi | L. Villaruz | P. Souquet | B. Johnson | M. Tan